Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 4/20 | 0.40 |
| ▸ | LTA4H | P09960 | 7/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945993 | 0.85 | KMT2A (0.49) | S1PR1CASP3RECQLG6PDMAPT | |
| SCHEMBL15195144 | 0.84 | S1PR1 (0.44) | S1PR1CASP3LTA4HRECQLG6PD | |
| SCHEMBL7945044 | 0.77 | RAB9A (0.52) | CASP3G6PDMAPTKMT2ALMNA | |
| SCHEMBL7950445 | 0.75 | MAPT (0.60) | MAPTLMNATP53SMN1; SMN2 | |
| SCHEMBL7940591 | 0.72 | GAA (0.46) | CASP3MAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL20253483 | 0.69 | HDAC8 (0.50) | S1PR1LTA4HKMT2A | |
| SCHEMBL12230833 | 0.68 | CASP3 (0.53) | CASP3G6PDMAPTKMT2ALMNA | |
| SCHEMBL7407960 | 0.67 | LTA4H (0.56) | LTA4H | |
| SCHEMBL23881677 | 0.62 | F2 (0.49) | SMN1; SMN2 | |
| SCHEMBL1374371 | 0.62 | S1PR1 (0.68) | S1PR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301208-A1 | VIRAL AND FUNGAL INHIBITORS | WICHITA STATE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301208-A1 | VIRAL AND FUNGAL INHIBITORS | WICHITA STATE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010039534-A2 | VIRAL AND FUNGAL INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301208-A1 | VIRAL AND FUNGAL INHIBITORS | HAVCR2, ZC3HAV1, ERG28 | S1PR1 994/4885CASP3 1969/4885LTA4H 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.